Discrimination of normal oral mucosa from oral cancer by mass spectrometry imaging of proteins and lipids.
Head and neck cancer
Lipidomics
Mass spectrometry
Molecular classification
Molecular imaging
Proteomics
Journal
Journal of molecular histology
ISSN: 1567-2387
Titre abrégé: J Mol Histol
Pays: Netherlands
ID NLM: 101193653
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
11
09
2018
accepted:
29
10
2018
pubmed:
6
11
2018
medline:
5
2
2019
entrez:
4
11
2018
Statut:
ppublish
Résumé
Identification of biomarkers for molecular classification of cancer and for differentiation between cancerous and normal epithelium remains a vital issue in the field of head and neck cancer. Here we aimed to compare the ability of proteome and lipidome components to discriminate oral cancer from normal mucosa. Tissue specimens including squamous cell cancer and normal epithelium were analyzed by MALDI mass spectrometry imaging. Two molecular domains of tissue components were imaged in serial sections-peptides (resulting from trypsin-processed proteins) and lipids (primarily zwitterionic phospholipids), then regions of interest corresponding to cancer and normal epithelium were compared. Heterogeneity of cancer regions was higher than the heterogeneity of normal epithelium, and the distribution of peptide components was more heterogeneous than the distribution of lipid components. Moreover, there were more peptide components than lipid components that showed significantly different abundance between cancer and normal epithelium (median of the Cohen's effect was 0.49 and 0.31 in case of peptide and lipid components, respectively). Multicomponent cancer classifier was tested (vs. normal epithelium) using tissue specimens from three patients and then validated with a tissue specimen from the fourth patient. Peptide-based signature and lipid-based signature allowed cancer classification with a weighted accuracy of 0.85 and 0.69, respectively. Nevertheless, both classifiers had very high precision (0.98 and 0.94, respectively). We concluded that though molecular differences between cancerous and normal mucosa were higher in the proteome domain than in the analyzed lipidome subdomain, imaging of lipidome components also enabled discrimination of oral cancer and normal epithelium. Therefore, both cancer proteome and lipidome are promising sources of biomarkers of oral malignancies.
Identifiants
pubmed: 30390197
doi: 10.1007/s10735-018-9802-3
pii: 10.1007/s10735-018-9802-3
pmc: PMC6323087
doi:
Substances chimiques
Biomarkers
0
Lipids
0
Proteome
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-10Subventions
Organisme : Narodowe Centrum Nauki
ID : 2016/23/B/NZ4/03901
Organisme : Narodowe Centrum Nauki
ID : 2015/19/B/ST6/01736
Organisme : Narodowe Centrum Badań i Rozwoju
ID : DZP/STATEGMED2/2554/2014
Organisme : Narodowe Centrum Badań i Rozwoju
ID : POIG.02.03.01-24-099
Organisme : Politechnika Śląska
ID : BKM/508/RAU1/2017/t.28
Références
Mol Cell Proteomics. 2005 Apr;4(4):394-401
pubmed: 15677390
Anal Chem. 2005 Sep 1;77(17):5655-61
pubmed: 16131078
Mass Spectrom Rev. 2007 Jul-Aug;26(4):606-43
pubmed: 17471576
Radiother Oncol. 2007 Oct;85(1):156-70
pubmed: 17482300
Nat Methods. 2007 Oct;4(10):828-33
pubmed: 17901873
J Proteome Res. 2008 Jan;7(1):113-22
pubmed: 18067247
J Proteome Res. 2010 Feb 5;9(2):1157-64
pubmed: 19821573
J Proteome Res. 2009 Dec;8(12):5674-8
pubmed: 19848406
J Proteome Res. 2010 May 7;9(5):2182-90
pubmed: 20141219
Nat Rev Cancer. 2010 Sep;10(9):639-46
pubmed: 20720571
Trends Biotechnol. 2011 Mar;29(3):136-43
pubmed: 21292337
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
Oral Oncol. 2012 Mar;48(3):240-8
pubmed: 22104250
FEBS J. 2012 Aug;279(15):2610-23
pubmed: 22621751
J Cancer Res Clin Oncol. 2013 Jan;139(1):85-95
pubmed: 22955295
Clin Biochem. 2013 Apr;46(6):539-45
pubmed: 23388677
Int J Cancer. 2013 Nov;133(9):2013-23
pubmed: 23417723
J Proteome Res. 2013 Apr 5;12(4):1847-55
pubmed: 23480610
Anal Bioanal Chem. 2014 Feb;406(5):1307-16
pubmed: 23728729
Int J Oncol. 2014 Feb;44(2):530-8
pubmed: 24253341
Science. 2014 Jan 17;343(6168):309-13
pubmed: 24436421
J Pathol. 2015 Jan;235(1):3-13
pubmed: 25201776
Lab Invest. 2015 Apr;95(4):422-31
pubmed: 25621874
J Biol Chem. 2015 Apr 10;290(15):9571-87
pubmed: 25720493
Int J Mol Sci. 2015 Jul 08;16(7):15497-530
pubmed: 26184160
PLoS One. 2015 Jul 31;10(7):e0134256
pubmed: 26230717
Arch Oral Biol. 2016 Mar;63:53-65
pubmed: 26691574
Oncotarget. 2016 Feb 2;7(5):5598-612
pubmed: 26734996
Oncogenesis. 2016 Jan 25;5:e189
pubmed: 26807644
Proteomics. 2016 Jun;16(11-12):1613-21
pubmed: 27168173
Mol Cancer. 2017 Apr 11;16(1):76
pubmed: 28399876
Nat Rev Cancer. 2018 May;18(5):269-282
pubmed: 29497144